Peptides are essential tools in modern drug discovery, structural biology, immunology, and diagnostics. As research targets grow more complex — from intrinsically disordered proteins to intracellular protein–protein interactions — the demand for chemically precise, highly pure, and functionally modified peptides continues to grow.
ICDMO's peptide synthesis platform is built on Fmoc solid-phase peptide synthesis (SPPS) chemistry, enabling rapid, scalable production of sequences from 5 to 150 amino acids with outstanding sequence fidelity. Our portfolio extends well beyond standard linear peptides: we offer cyclic and stapled peptides for structural rigidity, post-translational modification mimics for epigenetic and signalling research, fluorescently labelled tracers for imaging and assay development, and GMP-grade clinical peptides for IND submissions.
Every peptide is characterised by analytical reverse-phase HPLC and ESI or MALDI mass spectrometry before delivery. A full Certificate of Analysis is included with each order.
Crude
>60%
Preliminary screening, activity pilot
Desalted
>70%
ELISA antigens, WB standards
>95% Purified
>95%
Cell assays, in vivo studies, structural
GMP-Grade
>98%
Clinical use, IND/IMPD submissions
Platform Highlights
5–150
Amino Acids
Routine synthesis up to 50 aa; specialist long-chain peptides up to 150 aa with fragment condensation
100+
Modification Types
Side-chain and backbone modifications including phosphorylation, methylation, fluorescent labels and stapling
>98%
Max Purity
HPLC-grade peptides verified by reverse-phase HPLC and ESI-MS with full CoA delivered with every order
5–10
Business Days
Standard turnaround for peptides up to 30 aa at ≥95% purity; expedited options available
Core Services
🧪
Linear SPPS
Standard Custom Peptide Synthesis
Solid-phase peptide synthesis (SPPS) using Fmoc chemistry for sequences from 5 to 100+ amino acids. Four purity grades are available — crude (>60%), desalted, ≥85%, ≥95%, and ≥98% — each verified by analytical RP-HPLC and ESI-MS. Deliverables include the lyophilised peptide, a Certificate of Analysis, and HPLC/MS data.
Over 100 chemical modifications are routinely incorporated, including phosphorylation (pSer, pThr, pTyr), acetylation, methylation, biotinylation, PEGylation, and fluorescent dye labelling (FITC, FAM, TAMRA, Cy3, Cy5, and others). N- and C-terminal modifications (free acid, amide, PEG, fatty acid conjugation) are also supported for half-life extension and cell-penetration studies.
Cyclisation dramatically improves proteolytic stability, conformational rigidity, and membrane permeability. ICDMO supports four cyclisation chemistries: head-to-tail amide bond cyclisation, disulfide bridge (Cys–Cys), lactam bridge (Lys ε-amine to Asp/Glu side-chain carboxyl), and thioether (maleimide–Cys). All cyclic peptides are confirmed by NMR or ESI-MS.
Systematic peptide arrays for epitope mapping, SAR studies, and lead optimisation. Library formats include: truncation scan (progressive N/C terminal deletion), alanine scan (single-residue alanine substitution), positional scanning synthetic combinatorial libraries (PS-SCL), and scrambled control peptides. Supplied as individual tubes or in 96-well plate format.
Clinical and pharmaceutical-grade peptide production under ICH Q7 guidelines, with full batch documentation, process validation, and release testing. Capabilities include multi-gram to kilogram-scale synthesis, impurity profiling by LC-MS/MS, residual solvent analysis, sterility and endotoxin testing, and audit-ready documentation packages for IND/IMPD submissions.
Chemical modification dramatically expands the functional repertoire of synthetic peptides — enabling cell entry, site-specific detection, stability enhancement, and faithful mimicry of post-translational events. ICDMO supports over 100 modification types across six major categories:
Post-translational Mimics
Phospho-Ser/Thr/Tyr
Acetyl-Lys (Kac)
Methyl-Lys/Arg
Succinyl-Lys
Ubiquitin-tag (GlyGly-Lys)
Fluorescent Labels
FITC / FAM
TAMRA / ROX
Cy3 / Cy5
BODIPY series
DANSYL
Affinity & Detection Tags
Biotin (N/C-term or Lys)
Streptavidin binding peptide
His-tag peptides
FLAG / HA tag
Desthiobiotin
Half-life Extension
PEGylation (2k–40k Da)
Fatty acid (C16/C18) conjugation
Albumin-binding moieties
XTEN-mimetic sequences
GLP-1/GIP analogue scaffolds
Backbone & Terminal
N-terminal acetylation
C-terminal amidation
N-methylation
β-amino acids
D-amino acid substitution
Cell-Penetrating
CPP fusion (Tat, penetratin)
Lipidation
Stearyl / myristoyl
Cholesterol conjugation
Arginine-rich arrays
Need a modification not listed? Contact our synthesis team — we regularly source novel Fmoc building blocks and can assess feasibility for bespoke projects.
Synthesis Workflow
All peptides are manufactured on a defined, quality-monitored production path from sequence submission through delivery of lyophilised product with full analytical data:
1
Sequence Design & Order
Submit sequence, desired length, purity grade, scale, and required modifications. Our team reviews for synthetic feasibility and flags difficult sequences (high aggregation propensity, repetitive motifs) before synthesis begins.
2
Resin Loading & SPPS
Fmoc solid-phase synthesis on optimised resins (Wang, Rink Amide, TCP, or 2-chlorotrityl). Coupling efficiency is monitored at each cycle; difficult couplings receive extended reaction time or pseudoproline dipeptide insertion.
3
Cleavage & Global Deprotection
Treatment with TFA cocktail releases the peptide from the resin and simultaneously removes all side-chain protecting groups. The crude mixture is precipitated in cold diethyl ether and collected by filtration.
4
Purification by RP-HPLC
Preparative reverse-phase HPLC (C18 or C8, gradient elution) achieves target purity from crude to ≥98%. Fractions are collected, pooled, and assessed by analytical HPLC before lyophilisation.
5
Quality Control Analysis
Every peptide is characterised by analytical RP-HPLC (purity %) and ESI-MS or MALDI-TOF (mass confirmation). GMP-grade peptides additionally receive residual solvent testing, endotoxin (LAL), and microbial limit tests.
6
Lyophilisation & Delivery
Purified peptides are lyophilised to a dry powder and packaged under inert atmosphere. Each shipment includes a Certificate of Analysis (CoA) with HPLC chromatogram, MS spectrum, purity, yield, and storage recommendations.
📊
RP-HPLC Analysis
Purity determined by area normalisation on C18 column, gradient elution, UV 214 nm. Chromatogram included in CoA.
⚖️
ESI-MS / MALDI-TOF
Molecular weight confirmation; isotope pattern analysis for modified peptides. Spectrum provided with delivery.
📄
Certificate of Analysis
Sequence, MW, purity %, yield, storage conditions, and all raw QC data bundled with every shipment.
Request a Peptide Synthesis Quote
Submit your sequence and requirements below. Our team will respond with a detailed quotation, feasibility assessment, and estimated turnaround within one business day.